ARHGAP19 Activators are a collection of chemical compounds that enhance the Rho GTPase-activating protein function of ARHGAP19 through various intracellular signaling pathways and mechanisms. Forskolin, by raising cAMP levels, indirectly promotes the activity of ARHGAP19 by facilitating actin cytoskeleton rearrangements that are critical for ARHGAP19's function, via PKA-dependent mechanisms. Similarly, PMA's activation of PKC can lead to phosphorylation of proteins that interact with ARHGAP19, potentiating its regulatory role in modulating Rho-family GTPases. Y-27632, a ROCK inhibitor, and Calpeptin, a calpain inhibitor, function by altering phosphorylation patterns and stabilizing cellular structures where ARHGAP19 operates, respectively, thereby enhancing its availability and activity. ML-7's inhibition of MLCK and the subsequent reduction in myosin II activity is another route throughwhich ARHGAP19's GAP domain is made more accessible to its targets, facilitating the hydrolysis of GTP bound to Rho GTPases.
The biochemical landscape for ARHGAP19 is further refined by compounds targeting various other kinases and signaling molecules. NSC 23766 stifles the Rac1-GEF interaction, skewing the balance in favor of RhoA GTP hydrolysis, a process augmented by ARHGAP19, while inhibitors like LY294002 and U73122 modulate lipid signaling, therefore influencing ARHGAP19's role in Rho GTPase regulation. PD98059 and SB203580, which inhibit MEK and p38 MAPK respectively, contribute to shifting signaling equilibria that could sequester ARHGAP19, thus freeing it to deactivate RhoA more efficiently. Blebbistatin's action on myosin II ATPase and Gö 6983's broad inhibition of PKC isoforms result in a cellular environment that favors ARHGAP19-mediated inactivation of Rho GTPases. Collectively, these activators enhance the functional activity of ARHGAP19 by modulating the signaling pathways and cellular processes that are intimately connected to its regulatory role in actin cytoskeleton dynamics and cellular morphology.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Forskolin | 66575-29-9 | sc-3562 sc-3562A sc-3562B sc-3562C sc-3562D | 5 mg 50 mg 1 g 2 g 5 g | $78.00 $153.00 $740.00 $1413.00 $2091.00 | 73 | |
Forskolin activates adenylate cyclase, increasing cAMP levels. Elevated cAMP enhances ARHGAP19 activity by promoting localized actin cytoskeleton rearrangements through PKA-dependent mechanisms. | ||||||
PMA | 16561-29-8 | sc-3576 sc-3576A sc-3576B sc-3576C sc-3576D | 1 mg 5 mg 10 mg 25 mg 100 mg | $41.00 $132.00 $214.00 $500.00 $948.00 | 119 | |
PMA activates protein kinase C (PKC) which can phosphorylate downstream effectors that interact with ARHGAP19, enhancing its GTPase-activating protein activity toward Rho-family GTPases. | ||||||
Y-27632, free base | 146986-50-7 | sc-3536 sc-3536A | 5 mg 50 mg | $186.00 $707.00 | 88 | |
Y-27632 inhibits the Rho-associated protein kinase (ROCK), leading to decreased phosphorylation of downstream targets, thus potentially relieving inhibition on ARHGAP19 GTPase activity. | ||||||
Calpeptin | 117591-20-5 | sc-202516 sc-202516A | 10 mg 50 mg | $121.00 $456.00 | 28 | |
Calpeptin inhibits calpain, a protease that can modulate cytoskeletal organization. Inhibition of calpain may stabilize structures where ARHGAP19 exerts its activity, thus enhancing its function. | ||||||
ML-7 hydrochloride | 110448-33-4 | sc-200557 sc-200557A | 10 mg 50 mg | $91.00 $267.00 | 13 | |
ML-7 inhibits myosin light chain kinase (MLCK), leading to reduced myosin II activity. This can alter cell contractility and morphology, potentially increasing the availability of ARHGAP19 to its substrates. | ||||||
NSC 23766 | 733767-34-5 | sc-204823 sc-204823A | 10 mg 50 mg | $151.00 $609.00 | 75 | |
NSC 23766 inhibits the interaction between Rac1 and its guanine nucleotide exchange factors (GEFs), thereby potentially enhancing ARHGAP19's role in RhoA signal termination by shifting the equilibrium toward GTP hydrolysis. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY294002 is a PI3K inhibitor. By inhibiting PI3K, it may reduce PIP3 levels, thus indirectly enhancing ARHGAP19-mediated Rho GTPase inactivation due to altered signaling dynamics. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
PD98059 is a MEK inhibitor that may lead to reduced ERK phosphorylation. As a result, it could enhance ARHGAP19 activity by decreasing competitive signaling pathways that sequester ARHGAP19 away from its RhoA substrate. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
SB203580 is a p38 MAPK inhibitor that may enhance ARHGAP19 activity indirectly by altering the actin cytoskeleton and adhesion dynamics, thus affecting ARHGAP19's cellular localization and function. | ||||||
(±)-Blebbistatin | 674289-55-5 | sc-203532B sc-203532 sc-203532A sc-203532C sc-203532D | 5 mg 10 mg 25 mg 50 mg 100 mg | $183.00 $313.00 $464.00 $942.00 $1723.00 | 7 | |
Blebbistatin inhibits myosin II ATPase activity, leading to changes in cell shape and tension. This could enhance ARHGAP19's function by affecting its interaction with Rho-family GTPases at the cellular cortex. | ||||||